Berlin, 7. Dezember 2022 – Aktuelle Empfehlungen zum Lieferengpass von Nanopartikel-Albumin-gebundenem Paclitaxel (nab-Paclitaxel)

• Literatur

• 1 Zugriff am 07. Dezember 2022 unter: https://anwendungen.pharmnet-bund.de/lieferengpassmeldungen/faces/public/meldungen.xhtml
• 2 Zugriff am 07. Dezember 2022 unter: https://register.awmf.org/de/start
• 3 Zugriff am 07. Dezember 2022 unter: https://www.onkopedia.com/de/onkopedia/guidelines
• 4 Zugriff am 07. Dezember 2022 unter: https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2022/Einzeldateien_Literatur/AGO_2022D_19_%20Chemotherapie_beim_met._MaCa_REF.pdf
• 5 West H, McCleod M, Hussein M. et al. Atezolizumab in combination with carboplatin plus nab- paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924-937
• 6 Frost N, Zhamurashvili T, von Laffert M. et al. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. Clin Lung Cancer 2020; 6: e607-e621
• 7 Gandhi L, Rodriguez-Abreu D, Gadgeel SM. et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 2078-2092
• 8 Socinski MA, Jotte RM, Cappuzzo F. et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-2301
• 9 Paz-Ares L, Ciuleanu TE, Cobo M. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 198-211
• 10 Ghersi D, Willson ML, Chan MM. et al. Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2015; (06) CD003366
• 11 Gradishar WJ, Krasnojon D, Cheporov A. et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611-3619
• 12 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108-2121
• 13 Von Hoff D, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703
• 14 Conroy T, Desseigne F, Ychoux M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825
• 15 Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F. et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013; 31: 23-29